EG12021 (bevacizumab biosimilar) / EirGenix - LARVOL DELTA

NSCLC: Standard Treatment Approaches for EGFR Exon 20 Insertion Mutations (OncLive) - "Erminia Massarelli, MD, MS, PhD: My standard treatment for patients with exon 20 insertion mutations in the first line-outside clinical trials, because at our institution [City of Hope] we do have many clinical trials-in non-small cell lung cancer has been with chemotherapy plus or minus immunotherapy....After progression of first line, we have many clinical trials. We participated in several that led to the approval of amivantamab and mobocertinib, and we have more ongoing trials."

Video